Atara Biotherapeutics (NASDAQ:ATRA) Coverage Initiated at Rodman & Renshaw

Equities researchers at Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research note issued on Friday,Benzinga reports. The brokerage set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s price objective suggests a potential upside of 119.30% from the stock’s previous close.

A number of other research analysts also recently issued reports on ATRA. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Canaccord Genuity Group raised their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Atara Biotherapeutics Stock Performance

NASDAQ:ATRA opened at $11.40 on Friday. The firm has a market cap of $65.66 million, a P/E ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The firm has a 50-day simple moving average of $10.80 and a two-hundred day simple moving average of $9.57.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to the consensus estimate of $23.00 million. During the same period last year, the business earned ($16.50) EPS. On average, equities research analysts predict that Atara Biotherapeutics will post -12.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ATRA. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $53,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter worth $79,000. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the last quarter. FMR LLC increased its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.